Literature DB >> 21893082

Participation of brainstem monoaminergic nuclei in behavioral depression.

Yan Lin1, Yasmeen Sarfraz, Ashley Jensen, Adrian J Dunn, Eric A Stone.   

Abstract

Several lines of research have now suggested the controversial hypothesis that the central noradrenergic system acts to exacerbate depression as opposed to having an antidepressant function. If correct, lesions of this system should increase resistance to depression, which has been partially but weakly supported by previous studies. The present study reexamined this question using two more recent methods to lesion noradrenergic neurons in mice: intraventricular (ivt) administration of either the noradrenergic neurotoxin, DSP4, or of a dopamine-β-hydroxylase-saporin immunotoxin (DBH-SAP ITX) prepared for mice. Both agents given 2 weeks prior were found to significantly increase resistance to depressive behavior in several tests including acute and repeated forced swims, tail suspension and endotoxin-induced anhedonia. Both agents also increased locomotor activity in the open field. Cell counts of brainstem monoaminergic neurons, however, showed that both methods produced only partial lesions of the locus coeruleus and also affected the dorsal raphe or ventral tegmental area. Both the cell damage and the antidepressant and hyperactive effects of ivt DSP4 were prevented by a prior i.p. injection of the NE uptake blocker, reboxetine. The results are seen to be consistent with recent pharmacological experiments showing that noradrenergic and serotonergic systems function to inhibit active behavior. Comparison with previous studies utilizing more complete and selective LC lesions suggest that mouse strain, lesion size or involvement of multiple neuronal systems are critical variables in the behavioral and affective effects of monoaminergic lesions and that antidepressant effects and hyperactivity may be more likely to occur if lesions are partial and/or involve multiple monoaminergic systems.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893082      PMCID: PMC3199359          DOI: 10.1016/j.pbb.2011.08.021

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  107 in total

1.  Further evidence for an immediate antidepressant action of intracerebral drug administration in a model of chronic depression.

Authors:  Yan Lin; Raymond F Suckow; Yasmeen Sarfraz; Eric A Stone
Journal:  Int J Neuropsychopharmacol       Date:  2010-09-29       Impact factor: 5.176

2.  Dorsal and ventral medullary catecholamine cell groups contribute differentially to systemic interleukin-1beta-induced hypothalamic pituitary adrenal axis responses.

Authors:  K Buller; Y Xu; C Dayas; T Day
Journal:  Neuroendocrinology       Date:  2001-02       Impact factor: 4.914

3.  Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test.

Authors:  C López-Rubalcava; I Lucki
Journal:  Neuropsychopharmacology       Date:  2000-02       Impact factor: 7.853

4.  Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice.

Authors:  E A Stone; Y Zhang; H Rosengarten; J Yeretsian; D Quartermain
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

5.  Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone.

Authors:  M L Wong; M A Kling; P J Munson; S Listwak; J Licinio; P Prolo; B Karp; I E McCutcheon; T D Geracioti; M D DeBellis; K C Rice; D S Goldstein; J D Veldhuis; G P Chrousos; E H Oldfield; S M McCann; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

6.  Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and beta-adrenoceptor binding in the rat.

Authors:  J Harro; R Pähkla; M Harro; A Kask; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

7.  Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.

Authors:  Roya Abolfazli; Mahdi Hosseini; Ahmad Ghanizadeh; Ali Ghaleiha; Mina Tabrizi; Maedeh Raznahan; Mousa Golalizadeh; Shahin Akhondzadeh
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

8.  Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression.

Authors:  E A Stone; D Quartermain
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

9.  Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage.

Authors:  J W Murrough; K A Boss-Williams; M S Emery; R W Bonsall; J M Weiss
Journal:  Brain Res       Date:  2000-11-10       Impact factor: 3.252

Review 10.  The role of the locus coeruleus in the development of Parkinson's disease.

Authors:  M Gesi; P Soldani; F S Giorgi; A Santinami; I Bonaccorsi; F Fornai
Journal:  Neurosci Biobehav Rev       Date:  2000-08       Impact factor: 8.989

View more
  2 in total

1.  Antidepressant Effects of the Ginsenoside Metabolite Compound K, Assessed by Behavioral Despair Test and Chronic Unpredictable Mild Stress Model.

Authors:  Wu Song; Yan Guo; Shuang Jiang; Lin Wei; Zhi Liu; Xiaoyan Wang; Ying Su
Journal:  Neurochem Res       Date:  2018-05-22       Impact factor: 3.996

2.  Differential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the substantia nigra and locus coeruleus.

Authors:  Sarah C Hopp; Sarah E Royer; Heather M D'Angelo; Roxanne M Kaercher; David A Fisher; Gary L Wenk
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-16       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.